INVESTOR RELATIONS
Latest News
-
October 10, 2018
Evidence on the Safety and Efficacy of Ortho-R in a Large Animal Model Presented at 2018 SICOT World Congress. -
September 19, 2018
Ortho Regenerative Technologies Inc. Appoints Accomplished Life Science Executive, Luc Mainville, as CFO. -
September 6, 2018
Ortho RTi Signs Agreement with a leading CMO for the Manufacture of cGMP Finished Dosage Form Ortho-R in Preparation for Planned First-in-Human Study. -
August 31, 2018
Ortho Regenerative Technologies Inc. Announces CFO Change -
July 31, 2018
Ortho RTi Announces Extension of Certain Early Warrants -
July 19, 2018
Ortho RTi Announces Closing of Second Tranche of Non-Brokered Private Placement -
June 13, 2018
Ortho RTi Press Release Histopathology -
May 31, 2018
Ortho RTi Announces the Issuance of 3,610,000 Shares Pursuant to its Non-Brokered Private Placement -
May 25, 2018
Ortho RTi Announces Non-Brokered Private Placement -
May 23, 2018
Ortho RTi Receives Notice of Allowance for Second European Patent Protecting Ortho-R Technology -
April 2, 2018
Ortho RTi Announces Compelling Data from Ortho-R Pilot Study in Rotator Cuff Repair -
March 8, 2018
Ortho RTi Receives Notice of Allowance for European Patent Protecting Ortho-R Technology -
January 8, 2018
Ortho RTi Announces Changes to its Board of Directors -
December 20, 2017
Peer-Reviewed Article on Ortho RTi’s Ortho-R Implants to Aid in Meniscus Repair Published in Regenerative Medicine and Therapeutics -
December 19, 2017
Ortho RTi Expands Scientific Advisory Board with Appointment of Accomplished Orthopedic Surgeon, Dr. Jacques Toueg -
December 18, 2017
OrthoRTi approves E&Y as new auditors -
December 11, 2017
Ortho Regenerative looks to prevent surgery by turbocharging joint recovery process -
December 11, 2017
Ortho Regenerative Technologies Announces Final Closing of its Non-Brokered Private Placement -
December 6, 2017
Biomedical Materials has provided further validation that its “Ortho-R” hybrid implants release more growth factors and reside longer in the body than platelet rich plasma (“PRP”) alone. -
October 31, 2017
Issuance of 1,810,000 Units Pursuant to its Non-Brokered Private Placement -
October 27, 2017
Ortho Regenerative Technologies Announces Private Placement -
October 10, 2017
Ortho Begins Trading on the CSE -
October 3, 2017
Ortho appoints a renowned International Sports & Entertainment Industry board members -
September 6, 2017
Ortho Regenerative Technologies’ CSO, Michael Buschmann, PhD, Appointed Bioengineering Chair at George Mason University -
August 29, 2017
Accomplished Pharmaceutical Industry Executive Joins Ortho Regenerative Technologies as VP of Product Development -
April 4, 2017
Bio Tuesday article -
March 24, 2017
ORTHO REGENERATIVE TECHNOLOGIES TECHNOLOGY PLATFORM FRONT AND CENTER AT 2017 ORS ANNUAL MEETING -
October 18, 2016
Ortho announces changes in executive leadership -
August 26, 2016
Ortho Regenerative Technologies Inc. Announces Receiving Key Patent -
August 3, 2016
Ortho announces a private placement and closing of first tranche -
June 30, 2016
Ortho grants of options and appoints new CFO -
May 20, 2016
Ortho Regenerative Technologies Inc. Presents Advances in Tissue Repair in Multiple Podium Presentations and Posters at the 2016 World Biomaterials CongressMontreal, Canada, May 20th, 2016 - Ortho Regenerative Technologies Inc., a regenerative medical device company specializing in the repair of sports medicine injuries (the “Company”), announced today the presentation key technical advances in the mechanisms underlying the repair of soft tissue injuries through its proprietary biopolymer in 4 podium presentations and 2 poster presentations at the World Biomaterials Congress being held in Montreal, Canada from May 17-22, 2016.
-
December 9, 2015
MANITEX CAPITAL INC. AFFILIATE, ORTHO REGENERATIVE TECHNOLOGIES INC., ANNOUNCES THE APPOINTMENT OF DR. ED MARGERRISON AS PRESIDENT AND CEO